Vous êtes sur la page 1sur 22

7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

Author: Richard Lee, MD, MBA


Section Editors: Arie Pieter Kappetein, MD, PhD, Gabriel S Aldea, MD, Bradley P Knight, MD, FACC
Deputy Editor: Gordon M Saperia, MD, FACC

Contributor Disclosures

All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Oct 2017. | This topic last updated: Nov 17, 2016.

INTRODUCTION — Atrial fibrillation (AF) and atrial flutter occur frequently after cardiac surgery. The
development of these atrial arrhythmias prolongs hospital stay and is associated with worse long-term
prognosis. Other supraventricular arrhythmias, including atrial arrhythmias such as atrioventricular nodal re-
entrant tachycardia, are not common in this setting. (See "Atrioventricular nodal reentrant tachycardia".)

This topic will review the pathogenesis, predictors, clinical course, prevention, and management of AF and
atrial flutter occurring after cardiac surgery. Most of the observations on atrial arrhythmias come from patients
who developed atrial fibrillation. Our approach to patients with atrial flutter is similar, unless otherwise specified.

Ventricular tachyarrhythmias after cardiac surgery and arrhythmias after cardiac transplantation are discussed
separately. (See "Early cardiac complications of coronary artery bypass graft surgery", section on 'Ventricular
tachyarrhythmias' and "Arrhythmias following cardiac transplantation".)

PATHOGENESIS — Atrial fibrillation (AF) and atrial flutter can occur early in the postoperative period or as a
late complication of cardiac surgery. A discussion of the mechanisms of AF in the general population is found
elsewhere. (See "Mechanisms of atrial fibrillation".)

Postoperative AF is likely related to a combination of perioperative factors. These include pre-existing


degenerative changes in the atrial myocardium and perioperative conditions that result in abnormalities of
several electrophysiologic parameters that promote the development of AF, such as dispersion of atrial
refractoriness, increase in phase 3 depolarization, enhanced automaticity, increased interatrial conduction time,
and decreased conduction velocity, atrial transmembrane potentials, and fluid and electrolyte shifts [1-5]. (See
"The electrocardiogram in atrial fibrillation".)

RISK FACTORS — Although some patients develop atrial fibrillation (AF) after cardiac surgery without any
apparent predisposing factors, most patients have at least one clinical predictor. Preoperative risk factors
include [2,6-17]:

● Increasing age [6-12]


● Previous history of AF
● Mitral valvular disease, particularly mitral stenosis
● Increased left atrial size or cardiomegaly
● Previous cardiac surgery
● Chronic obstructive pulmonary disease (COPD)
● Elevated preoperative hemoglobin A1c [18]
● Low-intensity physical activity in the year prior to surgery [19]
● Caucasian race [20]
● Obesity [17,21]
● Absence of beta blocker or angiotensin converting enzyme inhibitor (ACE inhibitor) treatment or withdrawal
of previous treatment (see 'Prevention of AF and complications' below)
https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular%… 1/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

● Preoperative digoxin use in some [7,13] but not all studies [14]
● Higher preoperative plasma concentration of brain natriuretic peptide (BNP) [15] (see "Natriuretic peptide
measurement in heart failure")
● Low-dose dopamine [22]
● Severe right coronary artery stenosis [12]
● Preoperative increase in P wave duration on surface (>116 msec) [16] or on signal averaged (>140 msec)
ECG (figure 1) [9,23] (see "Use of the signal-averaged electrocardiogram in arrhythmia evaluation and
management")
● Hypokalemia and hypomagnesemia (See 'Pathogenesis' above.)

PERIOPERATIVE RISK FACTORS — Perioperative factors that have been implicated in the creation of atrial
susceptibility to atrial fibrillation (AF) or atrial flutter include:

● Pericarditis
● Atrial injury from surgical handling, or cannulation, atrial suture lines
● Acute atrial enlargement from pressure or volume overload
● Inadequate myocardial protection during cardiopulmonary bypass
● Atrial ischemia
● Long bypass and aortic cross-clamp times
● Hyperadrenergic state (eg, use of postoperative inotropic medications)
● Pulmonary complications, hypoxemia
● Inflammation [24,25] (See "Epidemiology of and risk factors for atrial fibrillation", section on 'Inflammation
and infection'.)
● Hypokalemia and hypomagnesemia [26-29]
● Oxidative stress [30]

While mechanisms specific to late AF have not been identified, atrial flutter in these patients is re-entrant and
may involve atypical isthmuses between natural barriers, atrial incisions, and scar as well as the cavotricuspid
isthmus [31-33].

Two potential negative risk factors are off-pump coronary artery bypass graft surgery (CABG) and preservation
of the anterior fat pad:

● Off-pump CABG ─ off-pump CABG is associated with a lower rate of postoperative AF than conventional
CABG in some [34-36], but not all [37], studies. (See "Off-pump and minimally invasive direct coronary
artery bypass graft surgery: Outcomes".)

● Preservation of the anterior fat pad ─ Some [38], but not all [39], studies have found lower rate of
postoperative AF with preservation of the anterior fat pad.

However, none of these risk factors has adequate predictive accuracy to identify the individual patient at risk for
postoperative atrial arrhythmia. As a result, risk models that use several factors have been created [6,40]. In
one study, a multivariable risk model was derived in a cohort of 3093 patients, and then tested in a validation
cohort of 1564 patients [6]. Predictors were identified for any postoperative AF as well as for recurrent AF. The
risk score for any postoperative AF successfully stratified patients into groups at low risk (AF incidence <17
percent), medium risk (AF incidence 17 to 52 percent), and high risk (AF incidence >52 percent) (table 1). While
we do not routinely use any of these risk models, they highlight the individual risks.

INCIDENCE AND TIME COURSE — Atrial fibrillation occurs in 15 to 40 percent of patients in the early
postoperative period following coronary artery bypass graft surgery (CABG) [1,6,41,42], in 37 to 50 percent
https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular%… 2/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

after valve surgery [1,7,8], and in as many as 60 percent undergoing valve replacement plus CABG [1,7]. The
incidence increases with increasing age [6-12].

Atrial arrhythmias occur most often within the first few days after surgery [1,6,9,11]. In a prospective, multicenter
study of 4657 patients undergoing surgery, the majority of first episodes of AF occurred by day two, while the
majority of recurrent episodes occurred by day three. Forty-three percent of patients with atrial fibrillation (AF)
had more than one episode [6].

Among patients with postoperative AF who have no prior history of atrial arrhythmias, the AF is usually self-
limited, as 15 to 30 percent convert within two hours and up to 80 percent in 24 hours [1,43,44]. The mean
duration of AF in one report was 11 to 12 hours [44] and more than 90 percent are in sinus rhythm six to eight
weeks following surgery [1,44-46]. In one report, for example, only 3 of 116 patients who developed AF after
CABG were still in AF at six weeks [45].

AF may also occur late after cardiac surgery and the incidence is likely higher than appreciated because many
patients may have continued asymptomatic episodes of AF. In a study of over 2000 patients enrolled in cardiac
rehabilitation programs after cardiac surgery, 11 percent of patients developed AF (4.4 percent new-onset AF)
[47]. Late postoperative AF was associated with adverse outcomes, including heart failure and
rehospitalization.

Atrial flutter is relatively uncommon compared to atrial fibrillation.

CLINICAL MANIFESTATIONS AND DIAGNOSIS — The development of atrial fibrillation or flutter after cardiac
surgery may or may not lead to symptoms, such as palpitations, or to a change in the hemodynamic status of
the patient. In some individuals with rapid ventricular rates, the blood pressure may fall and potentially be
associated with a decline in the urine output.

We are not aware of any studies that have systematically characterized the clinical manifestations of
postoperative atrial fibrillation (AF) in coronary artery bypass graft surgery patients. In our experience, about 90
percent of these individuals are symptomatic and about 15 percent are hemodynamically unstable.

The diagnosis of AF in this setting is usually not difficult as most patients are on continuous monitoring. All
patients should have documentation of the rhythm with a 12 lead electrocardiogram. (See "The
electrocardiogram in atrial fibrillation".)

ADVERSE OUTCOMES FOLLOWING AF — Potential adverse outcomes after the development of


postoperative atrial fibrillation (AF) include stroke, death, and prolongation of hospital stay:

● Postoperative AF has been associated with an increased risk of in-hospital stroke in some [7,41,48-52] but
not all series [53,54]. It is possible that underlying comorbidities, such as older age, cerebrovascular or
peripheral artery disease, and cardiopulmonary bypass time, are related to in-hospital stroke rather than
the arrhythmia itself [50,53-56]

● Postoperative AF may identify a subset of patients with increased in-hospital and long-term mortality
[6,25,41,42,57,58]. This was suggested by a retrospective study of 6475 patients undergoing coronary
artery bypass graft surgery (CABG) at a single institution, 994 (15 percent) of whom developed AF [41].
Patients with AF had significantly greater mortality in-hospital (7.4 versus 3.4 percent) and at four years (26
versus 13 percent). In a case-matched subset of 390 patients, the mortality at five years was significantly
higher in those with AF (20 versus 7 percent). On multivariate analysis, postoperative AF was a predictor of
long-term mortality in both the retrospective cohort (adjusted odds ratio 1.5) and the case-matched
population (odds ratio 3.4).

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular%… 3/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

In another study of 1832 patients who underwent CABG, patients with postoperative AF had a higher long-
term mortality (2.99 versus 1.34 per 100 person-years; adjusted hazard ratio 2.13, 95% CI 1.45-3.15)
during a median follow-up of 51 months [42]. Patients with AF were at higher risk of dying from systemic
embolism (adjusted hazard ratio 4.33, 95% CI 1.78-10.52), but not from other causes.

● Postoperative AF is associated with prolongation of the duration of hospitalization, with an increased length
of stay between three and five days in series from the 1990s [7,11,48,49]. However, this effect has become
less prominent with current cardiac surgical care [59,60]. In a 2008 report of 1832 patients who underwent
CABG, the development of AF significantly increased the length of hospital stay by 1.3 days [42].

It is not known whether the apparent increase in mortality is present to the same extent for patients with
transient or persistent AF.

PREVENTION OF AF AND COMPLICATIONS — We recommend therapies to prevent the development of


postoperative atrial fibrillation (AF) in patients undergoing cardiac surgery in an attempt to decrease the
duration of hospitalization, to possibly decrease the risk of in-hospital stroke and death, and to decrease the
need for anticoagulation in some patients.

Prevention of AF — The use of beta blockers, sotalol, amiodarone, atrial pacing, or antioxidant vitamins
lowers the risk of postoperative AF [61]. Beta blockers are the best studied of these therapies and we prefer
beta blockers to sotalol or amiodarone based on their ease of use and better safety profile. We do not
recommend atrial pacing in most cases. There have been no studies comparing the relative efficacy and safety
of the traditional antiarrhythmic drugs to antioxidant vitamins.

Beta blockers — Beta blocker administration is the most widely used prophylactic strategy based on
numerous studies showing benefit, ease of use, and cost considerations [1,6,10,14,59,62-65]. Meta-analyses of
randomized trials from 2002 and 2004 found that they reduced the risk of AF compared to placebo or no
therapy (odds ratios of 0.35, 95% CI 0.26-0.49 and 0.39, 95% CI 0.28-0.52) [59,66]. However, a larger 2006
meta-analysis of 31 trials including 4452 patients performed separate analyses based on whether non-study
beta blocker was allowed to be continued or not [67]. When trials confounded by postoperative non-study beta
blocker withdrawal were excluded, the effect of beta blockers, although still significant, was less (OR 0.69, 95%
CI 0.54-0.87). In addition, other between-trial differences (heterogeneity), such as control group event rates
which ranged between 5 and 54 percent, lead us to be unsure of the true magnitude of the benefit from beta
blockers in patients who have not previously received them.

The issue of whether some beta blockers lower the risk of postoperative AF more successfully than others has
not been well studied. In a meta-analysis of randomized trials with 601 patients that compared carvedilol to
metoprolol (succinate and tartrate), carvedilol reduced the incidence of AF (odds ratio 0.50, 95% CI 0.32-0.80)
[68].

The benefit is seen when beta blockers are begun prior to or immediately after surgery. We feel the evidence is
not strong enough for us to recommend one beta blocker over another. When possible, we start beta blockers
at least 48 hours before surgery, due to concerns about the induction of excessive bradycardia. In addition,
some experts are concerned about the increased risk of stroke seen in patients undergoing noncardiac surgery
who receive beta blockers soon before surgery. (See "Management of cardiac risk for noncardiac surgery",
section on 'Patients who may require preoperative initiation of therapy'.) If a patient is a candidate for initiation
of a beta blocker but presents within the 48-hour window, our reviewers have differing approaches. Some will
start low dose beta blocker at any time before surgery, while others will wait until after the patient has returned
to the intensive care unit and is deemed “stable.”

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular%… 4/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

The optimal duration of therapy for prevention of postoperative atrial arrhythmias is uncertain, but we often
continue the beta blocker until the first postoperative visit. However, many patients who undergo CABG have a
clear indication for the long-term use of beta blocker therapy (eg, previous myocardial infarction, left ventricular
systolic dysfunction with heart failure, or hypertension).

Sotalol — Sotalol is a class III antiarrhythmic agent that has beta blocking activity. A 2011 meta-analysis of
15 randomized studies of patients undergoing cardiac surgery found that sotalol lowered the risk of AF
compared to placebo (relative risk [RR] 0.55, 95% CI 0.45-0.66) [69]. Compared to beta blocker, sotalol was
more effective (14 versus 23 percent; RR=0.64 [CI, 0.50-0.84]). There was no significant difference in the rates
between sotalol and amiodarone. Risks of sotalol include torsade de pointes and bradycardia. (See
"Therapeutic use and major side effects of sotalol".)

Sotalol is effective when begun 24 to 48 hours before surgery or four hours after surgery [70,71].

Amiodarone — Amiodarone lowers the incidence of postoperative AF by about 40 to 50 percent [59,66,72-


77]. A 2006 meta-analysis of 18 trials that included nearly 3000 patients found that amiodarone lowered the risk
of AF or atrial flutter compared to placebo (odds ratio [OR] 0.48, 95% CI 0.40-0.57) [67].

However, amiodarone is associated with more adverse cardiac events compared to placebo, including
bradycardia requiring temporary pacing (5.7 versus 2 percent), and QT prolongation (1.3 versus 0 percent) [77].
(See "Monitoring and management of amiodarone side effects".)

Metoprolol was directly compared to amiodarone in an equivalence trial of 316 hemodynamically stable patients
who underwent CABG or valve surgery [78]. The rates of the development of AF were similar (23.9 and 24.8
percent, respectively).

A number of different preoperative regimens of amiodarone have been evaluated. It has been given orally one
to seven days before surgery [73,74], intravenously immediately after surgery [75], or intravenously for 24 hours
followed by oral therapy for four days [76]. The efficacy of these different regimens is illustrated by the following
observations:

● One study randomly assigned 124 patients to oral amiodarone or placebo for a minimum of seven days
prior to elective cardiac surgery, continuing the drug until discharge [73]. The mean total dose of
amiodarone administered was 4.8 grams over 13 days (600 mg/day for seven days followed by 200
mg/day until discharge). The amiodarone group had a significant reduction in the incidence of
postoperative atrial fibrillation (25 versus 53 percent) without any increase in fatal or nonfatal postoperative
complications.

● Other oral regimens that have been effective include those that begin five days before surgery or one day
before surgery [74].

● The efficacy of postoperative intravenous therapy was documented in the ARCH trial in which 300 patients
were randomly assigned to 1 gram of intravenous amiodarone per day for two days or placebo; therapy
was begun immediately after CABG [75]. Amiodarone significantly reduced the incidence of atrial fibrillation
(35 versus 47 percent for placebo), but did not lower the length of hospitalization (7.6 versus 8.2 days). In
another report, intravenous amiodarone begun on call to the operating room and continued for 48 hours,
followed by oral amiodarone for three days, also significantly reduced postoperative atrial fibrillation (6
versus 26 percent) [79].

Although some have suggested that amiodarone might be more effective than a beta blocker for the prevention
of atrial fibrillation after cardiac surgery [80], this was not confirmed in two meta-analyses [59,66].

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular%… 5/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

Antioxidant vitamins — Oxidative stress plays a role in ischemia-reperfusion injury, which occurs in open
heart surgery. It is also involved in the pathogenesis of AF. Based on limited supportive evidence, as well as the
absence of side effects in the short term or significant cost, we believe it is reasonable to give antioxidant
vitamins to lower the rate of postoperative AF. (See "Reperfusion injury of the heart", section on 'Arrhythmias'
and "Reperfusion injury of the heart", section on 'Antioxidant therapy' and 'Pathogenesis' above.)

A 2011 meta-analysis evaluating five randomized trials comprising 567 patients found that the prophylactic use
of the antioxidant vitamins C and E lowered the rate of postoperative AF (odds ratio 0.43, 95% CI 0.21-0.89)
[81]. The conclusion of the meta-analysis is limited by the inclusion of small, low-quality studies.

Subsequent to the meta-analysis, a small trial randomly assigned 203 patients scheduled to undergo on-pump
cardiac surgery to supplementation with n-3 PUFA (1 gram twice daily), vitamin C (1 g/day), and vitamin E (400
international units/day) or placebo [82]. n-3 PUFA was started approximately seven days and the vitamins two
days before surgery; treatment was continued until hospital discharge. The primary outcome of the occurrence
of electrocardiographically confirmed postoperative AF occurred significantly less often in the antioxidant
therapy group (9.7 versus 32 percent; relative risk 0.28, 95% CI 0.14-0.56). Due to the small number of events
(postoperative AF), as well as the unusually low relative risk found, we believe this trial provides weak evidence
in favor of antioxidant vitamins. In addition, we do not believe that the trial, which combined n-3 PUFA with
vitamins, changes our view that n-3 PUFA are of no benefit in this setting. (See "Fish oil and marine omega-3
fatty acids", section on 'Atrial fibrillation'.)

If antioxidant vitamins are given to prevent postoperative AF, we suggest using them with the timing and dosing
used in the above trial and adding them to another preventative therapy.

Atrial pacing — Atrial pacing to prevent postoperative AF has been examined in a number of studies. Most
[83-87], but not all [76,88,89], showed benefit. In a 2006 meta-analysis, pacing was associated with a
significant reduction in AF (OR 0.60, 95% CI 0.47-0.77) [67]. With regard to the optimal pacing strategy (eg, left
compared to right atrium or pacing from one or both atria), studies are not definitive [84-89]. Atrial pacing is not
considered an invasive procedure in these patients because placement of temporary pacing wires is routinely
done at the time of surgery.

Ineffective or possibly effective therapies — We do not recommend any of the following preventative
strategies to prevent the development of atrial arrhythmias:

● Digoxin – Digoxin, given preoperatively or postoperatively, does not appear to prevent AF [14,63,64,90].

● Antiarrhythmic drugs – Data about the prophylactic use of class I antiarrhythmic drugs to prevent
postoperative AF are limited. Procainamide appears to reduce the number of episodes and duration of AF
compared to placebo, but not the incidence of AF [91,92].

● Calcium channel blockers – Calcium channel blockers have uncertain utility in preventing AF after
cardiac surgery [63,93-96].

● Intravenous magnesium – Based on the fact that hypomagnesia is a risk factor for AF (see 'Risk factors'
above), magnesium supplementation has been evaluated as a possible therapy to reduce postoperative
atrial arrhythmias [97-102]. In a 2006 meta-analysis of 22 trials including 2896 patients, supraventricular
arrhythmias occurred significantly less often in patients treated with magnesium compared to controls
(odds ratio 0.57, 95% CI 0.42-0.77) [67]. However, there was no effect on hospital stay, perioperative
myocardial infarction, or mortality. There was also significant heterogeneity in the size of the effect among
trials, and the possibility of publication bias was suggested.

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular%… 6/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

In a 2012 meta-analysis of seven randomized trials (n = 1028), which were felt to have no heterogeneity (I2
= 0), intravenous magnesium reduced the incidence of postoperative AF (relative risk 0.64, 95% CI 0.50-
0.83) [103].

● Angiotensin inhibition – Although angiotensin converting enzyme (ACE) inhibitors and angiotensin II
receptor blockers (ARBs) have not previously been considered a specific therapy in patients with AF, a
number of observations suggest benefit in nonsurgical settings. (See "ACE inhibitors, angiotensin receptor
blockers, and atrial fibrillation".)

A significant reduction in the incidence of postoperative AF (20 versus 34 percent) with ACE inhibitors was
seen in an observational study of 4657 patients undergoing CABG [6]. However, in a study of 445 patients
randomly assigned to placebo, ramipril, or spironolactone one week to four days prior to cardiac surgery,
there was no significant difference in the rate of AF after surgery [104].

In a prospective study of 4657 patients undergoing CABG, postoperative AF occurred significantly less
often in patients who were treated preoperatively and postoperatively with ACE inhibitors compared to
those who were not (20 versus 34 percent, odds ratio 0.62) [6]. In addition, patients who had previously
been taking ACE inhibitors and were withdrawn from therapy had a significant increase in risk (46 percent,
odds ratio 1.69). The utility of these agents in preventing AF after cardiac surgery remains controversial,
however, as other studies have not found a significant benefit [105-107]. A retrospective analysis of 8889
patients undergoing CABG described an increase in major adverse events, including postoperative renal
dysfunction as well as AF, in patients receiving preoperative ACE inhibitors [108]. Given the inconsistency
in the results among these studies, we do not recommend preoperative ACE inhibitors specifically for
prevention of AF in patients undergoing CABG.

● Statins – Some, but not all, studies have shown that statins lower the rate of postoperative AF [109,110]. A
2015 meta-analysis of 17 randomized trials that compared statin therapy with either placebo or no therapy
prior to cardiac surgery (predominantly coronary artery bypass graft surgery) found that such treatment
reduced the incidence of postoperative AF (odds ratio 0.54, 95% CI 0.43-0.67), but failed to influence
short-term mortality or postoperative stroke [111,112]. However, the meta-analysis pointed out significant
limitations of the evidence.

The largest randomized trial of preoperative statin therapy was published after the meta-analysis. In the
STICS trial, 1922 patients in sinus rhythm scheduled for elective cardiac surgery (87 percent CABG) were
randomly assigned to receive perioperative rosuvastatin (20 mg daily) or placebo up to eight days before
surgery [110]. Any previously prescribed statin was stopped. The rate of the primary outcome of
postoperative AF within five days of surgery was similar in both groups (21.1 and 20.5 percent,
respectively; odds ratio 1.04, 95% CI 0.84-1.30). Of note, there was no difference in the rate of myocardial
injury within 120 hours after surgery. In addition, rosuvastatin was associated with a significant absolute
excess in the rate of postoperative acute kidney injury (24.7 versus 19.3 percent; p = 0.005).

Based upon established benefits of statin therapy in patients with coronary heart disease, all patients
should be on long-term statin. However, for patients who have not started statin therapy prior to CABG, we
suggest waiting until after surgery, as there is no clear evidence of benefit from preoperative initiation and
possible harm. (See "Medical therapy to prevent complications after coronary artery bypass graft surgery",
section on 'Statins'.)

● N-acetylcysteine – N-acetylcysteine (NAC) has the potential to protect against the development of
perioperative AF due to its antioxidant and anti-inflammatory properties. (See 'Pathogenesis' above.)

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular%… 7/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

This hypothesis was tested in a trial of 115 patients undergoing either CABG or valve surgery who were
randomly assigned to either NAC or placebo given one hour before and continued for 48 hours after
surgery [113]. The primary end point of an AF episode lasting longer than five minutes during
hospitalization was seen in 15 patients and was significantly less common in those who received NAC (5.2
versus 21.2 percent).

In a small study designed to evaluate the potential benefit of anti-inflammatory therapy (with NAC or
carvedilol), 311 patients undergoing cardiac surgery who had no history of AF were randomly assigned to
metoprolol, carvedilol, or carvedilol plus NAC [114]. The incidence of postoperative AF was significantly
lower in the carvedilol plus NAC group compared to either of the other two interventions (35.9, 24.0, and
8.7 percent, respectively).

● Colchicine – Colchicine reduces the incidence of the postpericardiotomy syndrome. (See "Post-cardiac
injury syndromes", section on 'Prevention'.)

The issue of whether colchicine can reduce the incidence of postoperative AF was addressed in a post hoc
substudy. In COPPS, 360 patients undergoing cardiac surgery were randomly assigned to either colchicine
1.0 mg given twice daily on day one followed by 0.5 mg twice daily for one month (the dose was halved in
patients <70 kg) or placebo [115]. The first dose was given on postoperative day three. The COPPS
Prevention of Atrial Fibrillation (POAF) substudy evaluated outcomes in the 336 patients in sinus rhythm on
day three. Colchicine significantly reduced the incidence of postoperative AF (12 versus 22 percent;
relative risk reduction 45.5 percent, 95% CI 34.0-94.0 percent) at 30 days. In addition, patients taking
colchicine had a significantly shorter in-hospital stay (9.4 versus 10.3 days). There was a trend toward a
higher rate of side effects (9.5 versus 4.8 percent) and drug withdrawal (11.8 versus 6.6 percent) with
colchicine, but no severe side effects were recorded.

In the COPPS-2 trial, 360 patients scheduled for cardiac surgery were randomly assigned to oral colchicine
or placebo before surgery [116]. The drug was continued for one month after surgery. At three months,
there was no significant difference between the two groups in the secondary end point of postoperative AF
(34 versus 41 percent, respectively). (See "Post-cardiac injury syndromes", section on 'Prevention'.)

We believe there is insufficient evidence to recommend the routine use of colchicine, in part out of a
concern that it may negatively impact wound healing and that it leads to gastrointestinal side effects. The
2014 American Heart Association/American College of Cardiology/Heart Rhythm Society AF guideline
states that colchicine may be considered [117,118].

● Fish oil – The potential role of fish oil to reduce the incidence of postoperative AF after CABG is discussed
elsewhere. (See "Fish oil and marine omega-3 fatty acids", section on 'Atrial fibrillation'.)

● Naproxen – The potential benefit from naproxen was evaluated in the NAFARM trial, which randomly
assigned 161 patients to either naproxen or placebo [119]. There was no significant difference in the rate of
postoperative AF (7 versus 15 percent, respectively). The study was stopped early because of an increase
in renal failure in the naproxen group.

● Glucocorticoid – Based upon the hypothesis that perioperative inflammation may contribute to the
development of AF, glucocorticoids have been suggested as prophylactic therapy. (See "Glucocorticoid
effects on the immune system".)

Two meta-analyses of small trials in which glucocorticoid treatment was compared to placebo or no
https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular%… 8/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

treatment in adult cardiac surgery found 26 and 40 percent reductions in the incidence of AF, irrespective
of the dose given [120,121]. However, the large, randomized SIRS trial, published after the meta-analyses,
found no difference in the rate of new AF [122]. Due to their potential adverse effects on glucose
metabolism, wound healing, infection, and the absence of a lowering of the risk of death, we do not
recommend the routine use of glucocorticoid therapy to prevent AF.

The potential role for glucocorticoid therapy for other outcomes is discussed separately. (See "Medical
therapy to prevent complications after coronary artery bypass graft surgery", section on 'Glucocorticoid
therapy'.)

Prevention of complications of AF — While beta blockers, sotalol, amiodarone, and pacing decrease the risk
of postoperative AF, the evidence is less robust that the risk of complications such as stroke, death, or length of
stay can be prevented. It may be difficult to demonstrate a lowering of the risk of in-hospital stroke with these
therapies, as AF is only one risk factor for stroke and as the incidence of stroke is low. (See 'Adverse outcomes
following AF' above.)

The best available evidence of the impact of these interventions on the complications of AF comes from a 2006
meta-analysis of heterogenous trials, which noted the following [67]:

● In 29 trials that evaluated length of stay, only amiodarone and pacing shortened the average length of stay
(-0.60 days, 95% CI -0.92 to -0.29 and -1.3 days 95% CI -2.55 to -0.08, respectively).

● In 25 trials that reported on the incidence of postoperative stroke, the risk of stroke was decreased from 1.9
to 1.1 percent with treatment (odds ratio 0.63, 95% CI 0.41-0.98). Amiodarone was the only single
intervention that significantly lowered the risk of stroke compared to placebo.

Our approach to prevention — We recommend preventative therapy to reduce the incidence of postoperative
AF, especially in patients at high risk of its development. While the evidence is not robust, prevention of AF may
lead to a lowering of the risk of in-hospital stroke and a shortened length of stay. In addition, successful
prevention of AF will prevent the need for anticoagulation in some patients. Beta blockers, sotalol, amiodarone,
and atrial pacing are significantly more effective than placebo in lowering the rate of postoperative AF
[59,66,67]. There is some evidence to support the use of antioxidant vitamins for this purpose.

We prefer beta blockers to amiodarone or sotalol due to lower cost and lower risk of potential side effects and
to pacing because of its relative complexity and cost. Amiodarone or sotalol is a reasonable alternative in
patients who cannot tolerate beta blockade. If possible, we prefer to start beta blockers prior to CABG. We
suggest metoprolol 25 mg twice daily; the dose can be titrated postoperative based on the heart rate and blood
pressure. We continue this therapy until the first postoperative visit, unless there is a contraindication.

The evidence to support the use of antioxidant vitamins is less robust than that for traditional antiarrhythmic
drugs. While awaiting larger randomized trials, we believe it is reasonable to use antioxidant therapy as given in
the small randomized trial [82].

MANAGEMENT — While prevention with beta blockers, amiodarone, sotalol, or pacing lowers the risk of
postoperative atrial fibrillation (AF), many patients still develop AF (see 'Prevention of AF' above). We are
uncertain as to the optimal management of these patients, in part because it is not known whether
postoperative AF represents the same arrhythmia as AF occurring without cardiac surgery or if it possesses a
similar natural history in terms of portending adverse events.

We think the initial management should include correction of predisposing factors such as hypoxemia,
electrolyte abnormalities, and hemodynamic instability as well as pain management and withdrawal of

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular%… 9/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

stimulating factors such as inotropic agents. Subsequent management relates to the issues of rate control
versus rhythm control cardioversion and anticoagulation [123].

Options for management of AF include rate or rhythm control strategies. For patients with atrial flutter, we
cardiovert to sinus rhythm prior to discharge in most cases, as this rhythm is more difficult than AF to control
medically.

Rate control — Given the transient nature of the arrhythmia (see 'Incidence and time course' above), initial
control of the ventricular response rate is an effective and relatively safe strategy in many patients who develop
postoperative AF [43,124].

Rate control is most commonly achieved with beta blockers. The benefit is partly due to blockade of the
augmented postoperative sympathetic state and to prevention of beta blocker withdrawal in patients on beta
blockers preoperatively. Intravenous esmolol, a beta blocker with a short half-life, can be given for acute rate
control if there is a concern for bradyarrhythmias, hypotension, or bronchospasm. Slowing of the ventricular
rate in many AF patients receiving inotropic agents postoperatively can be achieved by lowering the dose or
discontinuation of these agents.

The optimal rate goal for patients with AF after cardiac surgery has not been determined. As these patients vary
widely in many clinical features (co-morbidities, need for rapid ventricular rate, etc), we suggest that the optimal
ventricular rate be determined on a case by case basis. In many patients, a ventricular rate of less than 110
beats per minute will prevent symptoms such as palpitations and allow for optimal cardiac performance. (See
"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy", section on 'Rate control goals'.).

Calcium channel blockers and digoxin are other atrioventricular (AV) nodal blockers that can control the
ventricular rate in AF, but they are not more effective than beta blockers. In patients in whom alternate agents
have not been successful in controlling the rate in atrial fibrillation, intravenous amiodarone can be used to slow
the ventricular response. (See "Control of ventricular rate in atrial fibrillation: Pharmacologic therapy".)

Rhythm control — Restoration of sinus rhythm from well-tolerated postoperative AF is usually not necessary
but occasionally can be beneficial. (See 'Incidence and time course' above.)

Restoration of sinus rhythm is indicated in symptomatic patients or in those when rate control is difficult to
achieve. An attempt at the restoration of sinus rhythm can be beneficial in patients with a low ejection fraction.
In addition, cardioversion in asymptomatic patients may be reasonable when well-tolerated AF occurs near the
time of anticipated hospital discharge or when it does not spontaneously terminate within 24 hours, so that oral
anticoagulation can be avoided; this is particularly true in patients at high risk of bleeding. We believe that an
attempt at cardioversion with either electrical or pharmacologic therapy is reasonable. The choice between the
two should be made on local practice and patient conditions.

Electrical therapy of AF involves direct current external transthoracic cardioversion and it is effective in
approximately 95 percent of cases [125] (see "Cardioversion for specific arrhythmias"). For patients who are
refractory to transthoracic cardioversion or when reversion is desirable but the patient's respiratory status
makes anesthesia for electrical conversion potentially difficult, pharmacologic therapy with intravenous sotalol
or amiodarone is reasonable. (See 'Sotalol' above and 'Amiodarone' above.)

The efficacy of antiarrhythmic drugs for reversion of postoperative AF is similar to that in AF not related to
surgery [126-134]. (See "Atrial fibrillation: Cardioversion to sinus rhythm".)

Rate versus rhythm control — For patients who do not spontaneously revert to sinus rhythm within a few
hours, rate control and rhythm control (with or without electrical cardioversion) appear to be comparable
strategies [44,45,135]. The choice between the two strategies should take into account patient and physician

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 10/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

preferences. Advantages of a rate control strategy include the absence of side effects from drug therapy;
disadvantages include a slower resolution of AF, thereby leading to a potentially greater need for
anticoagulation at discharge. In many patients, we chose a rhythm control strategy.

In a study of patients with no history of AF undergoing cardiac surgery, 523 individuals were randomly assigned
to either rate or rhythm control [135]. In the rate control group, the heart rate goal was less than 100 beats per
minute and in the rhythm control group, amiodarone was given with or without a rate slowing drug. If AF
persisted for 24 to 48 hours, electrical cardioversion was recommended. The primary end point was the total
number of days of hospitalization within 60 days after randomization. There was no difference between the two
groups in the primary outcome (median, 5.1 and 5 days, respectively; p = 0.76). This study had limitations, such
as including heterogenous patients and lacking the power to assess effect on death or serious adverse events.

Anticoagulation

Patients on long-term anticoagulant — For AF patients who are taking warfarin or direct oral
anticoagulants, we suggest stopping this therapy at least three days before surgery. We restart oral
anticoagulant therapy three to five days after surgery. The role of bridging heparin therapy for patients at high
risk of an embolic complication while off oral anticoagulant, such as those with AF and a prior embolic event, is
discussed elsewhere. (See "Perioperative management of patients receiving anticoagulants".)

Patients not taking anticoagulant prior to cardiac surgery — Patients with AF or atrial flutter, regardless
of the setting, are at risk for thromboembolic events; the magnitude of that risk varies based upon a number of
factors. Thromboembolic risk is primarily limited to AF or atrial flutter of more than 48 hours duration and is
greater in patients with certain high risk features (eg, rheumatic mitral valve disease, previous
thromboembolism, hypertension, or heart failure) (table 2) [123]. The general recommendations for
anticoagulation in patients with AF are discussed in detail elsewhere. (See "Atrial fibrillation: Anticoagulant
therapy to prevent embolization" and "Prevention of embolization prior to and after restoration of sinus rhythm
in atrial fibrillation" and "Embolic risk and the role of anticoagulation in atrial flutter".)

Patients who develop AF after cardiac surgery are at risk of thromboembolic events, including in-hospital
stroke. However, in the individual post-surgical patient with an embolic event, the cause may be unclear, as
underlying comorbidities are often responsible for such strokes, rather than the arrhythmia itself [53,59,136].
(See 'Incidence and time course' above.)

Based on evidence that oral anticoagulant therapy prevents episodes of systemic embolization in the broad
population of patients with atrial fibrillation, we believe that such therapy will lead to fewer embolic events in
patients with postoperative AF. However, a reduction of events with anticoagulant therapy in this population has
never been well studied. (See "Atrial fibrillation: Anticoagulant therapy to prevent embolization", section on
'Summary and recommendations'.)

As factors other than AF contribute to in-hospital stroke rates, it is not clear that aggressive early
anticoagulation (eg, intravenous heparin as a bridge to warfarin) will reduce the incidence of stroke. In addition,
the bleeding risk associated with anticoagulation in the immediate postoperative period (within the first 48 hours
in most patients) makes the overall impact of this approach less certain. The potential complications associated
with anticoagulation were illustrated in several observational series of patients who were treated with
intravenous heparin or oral anticoagulants for a variety of indications [137-139]. When closely monitored,
complication rates appear to be low [137,138]. However, one report found a significant increase in large
pericardial effusions and tamponade in patients treated with warfarin, particularly when the International
normalized ratio (INR) was above the therapeutic target [139]. These large effusions all occurred one week or
more after surgery. Thus, when anticoagulation is initiated, the patient must be monitored carefully. (See
"Perioperative management of patients receiving anticoagulants".)
https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 11/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

Similarly, the optimal duration of anticoagulation after hospital discharge is unknown. Among patients with new-
onset AF after cardiac surgery, many will revert to and maintain sinus rhythm [1,44-46].

Due to the inability to reverse their therapeutic effect, we do not start newer oral anticoagulants in the early
postoperative period. There are limited data at present, but this is an evolving strategy that may gain support as
our understanding evolves [140]. (See "Direct oral anticoagulants and parenteral direct thrombin inhibitors:
Dosing and adverse effects".)

Evidence is emerging that the left atrial appendage may play a major role in the development of stroke and
surgical elimination may obviate the need for anticoagulation. However, there are insufficient data at this time to
support routine surgical elimination.

Our approach to postoperative anticoagulation — Among patients who develop AF following cardiac
surgery, we suggest the following approach to anticoagulation:

● For patients with multiple episodes of AF or one episode that lasts more than 24 to 48 hours, we
recommend the initiation of oral anticoagulant therapy, but only if bleeding risks are considered acceptable.
As the role of direct thrombin and factor Xa inhibitors has not been established for patients with
postoperative AF, we suggest that warfarin be chosen for most patients (International normalized ratio 2.0-
3.0). (See "Atrial fibrillation: Anticoagulant therapy to prevent embolization", section on 'Select an
anticoagulant'.)

● We suggest continuation of anticoagulation for at least four weeks after return to sinus rhythm, particularly
if the patient has risk factors for thromboembolism. Longer duration of anticoagulation is recommended by
some of our experts in patients with high CHA2DS2-VASc scores (table 3), at low risk for bleeding based on
the HAS-BLED score (table 4), or at high risk of AF recurrence.

● Long-term anticoagulation should be considered for patients who remain in AF or who have paroxysmal AF
at four weeks. (See "Atrial fibrillation: Anticoagulant therapy to prevent embolization", section on 'Summary
and recommendations'.)

● We suggest maintaining oral anticoagulation in patients in which a concomitant Cox-Maze procedure has
been performed for at least three months, regardless of no postoperative atrial arrhythmias. (See "Surgical
ablation to prevent recurrent atrial fibrillation", section on 'Maze procedure'.) After three months with no AF
recurrence, anticoagulation may be interrupted, considering the patient risk profile for stroke by the
CHA2DS2-VASc score (table 3) [141].

In most cases, we do not use intravenous heparin as a bridge to full oral anticoagulation, as the risk of
postoperative bleeding outweighs the small benefit from stroke prevention. For patients with prior systemic or
pulmonary embolization or those with a mechanical valve, bridging anticoagulation with heparin may be
reasonable.

Both intravenous and oral anticoagulation should be monitored closely, as bleeding complications, including
pericardial effusion and tamponade increase with excessive anticoagulation.

RECOMMENDATIONS OF OTHERS — Guidelines from the American College of Cardiology


Foundation/American Heart Association and the European Society of Cardiology [141-144]. Our
recommendations are generally consistent with recommendations from these groups.

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected
countries and regions around the world are provided separately. (See "Society guideline links: Atrial fibrillation"
and "Society guideline links: Arrhythmias in adults".)

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 12/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

SUMMARY AND RECOMMENDATIONS

● Atrial fibrillation (AF) and atrial flutter occur frequently after cardiac surgery. Most episodes occur by the
third postoperative day. (See 'Incidence and time course' above.)

● Potential adverse outcomes of these atrial arrhythmias include a longer length of stay and in-hospital
stroke or death. (See 'Adverse outcomes following AF' above.)

● Beta blockers, sotalol, amiodarone, atrial pacing, and antioxidant vitamins lower the risk of the
development of AF and atrial flutter after cardiac surgery and may reduce the length of stay and lower the
risk of in-hospital stroke. (See 'Prevention of AF and complications' above.)

• We recommend therapy to prevent the development of adverse events associated with the
development of postoperative AF and atrial flutter (Grade 1B). (See 'Our approach to prevention'
above.)

• We recommend beta blockers rather than amiodarone or sotalol (Grade 1B). Beta blocker therapy
should be started prior to surgery and continued at least until the first postoperative visit unless
contraindicated. We prefer oral metoprolol 25 mg twice daily. For patients who cannot take beta
blockers, either amiodarone or sotalol may be used, with the decision based on patient characteristics
and physician familiarity. (See 'Our approach to prevention' above.)

• We suggest antioxidant therapy in addition to beta blocker therapy (Grade 2C). We start this therapy
two days prior to surgery and continue until discharge. We prefer the regimen of vitamin C (1 gram)
and vitamin E (400 international units), each given daily. (See 'Our approach to prevention' above.)

● For hemodynamically stable patients who develop postoperative AF, the optimal ventricular rate range
should be determined for each patient. In many patients, this rate will be less than 110 beats per minute.

● For patients who develop well-tolerated postoperative AF and whose rate is well controlled, we suggest not
performing cardioversion within the first 24 hours of its development (Grade 2B). Cardioversion may be
required within this time frame for those whose AF is poorly tolerated or whose rate is not well controlled.
(See 'Rhythm control' above.)

Cardioversion in asymptomatic patients may be reasonable when well-tolerated AF is present near the
time of anticipated hospital discharge, or when it does not spontaneously terminate within 24 to 48 hours,
so that oral anticoagulation can be avoided.

● For patients with multiple episodes of AF or one episode that lasts more than 24 to 48 hours, and if the
perioperative bleeding risks are considered reasonable, we recommend oral anticoagulation (Grade 1B).
(See 'Our approach to postoperative anticoagulation' above.)

We suggest anticoagulation with warfarin (international normalized ratio 2 to 3) rather than either a direct
thrombin or factor Xa inhibitor (Grade 2C).

For patients in whom anticoagulation is started and irrespective of the rhythm status at the time of
discharge from the hospital, we suggest continuation of anticoagulation for at least four weeks, rather than
stopping at the time of discharge (Grade 2C).

ACKOWLEDGMENT — The UpToDate editorial staff would like to thank Drs. John M. Stulak and Manuel
Castellá for their contributions as authors to previous versions of this topic review.

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 13/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

1. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001;
135:1061.
2. Cox JL. A perspective of postoperative atrial fibrillation in cardiac operations. Ann Thorac Surg 1993;
56:405.
3. Tsikouris JP, Kluger J, Song J, White CM. Changes in P-wave dispersion and P-wave duration after open
heart surgery are associated with the peak incidence of atrial fibrillation. Heart Lung 2001; 30:466.
4. Dupont E, Ko Y, Rothery S, et al. The gap-junctional protein connexin40 is elevated in patients susceptible
to postoperative atrial fibrillation. Circulation 2001; 103:842.
5. Karaca M, Demirbas MI, Biceroglu S, et al. Prediction of early postoperative atrial fibrillation after cardiac
surgery: is it possible? Cardiovasc J Afr 2012; 23:34.
6. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery.
JAMA 2004; 291:1720.
7. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann
Thorac Surg 1993; 56:539.
8. Asher CR, Miller DP, Grimm RA, et al. Analysis of risk factors for development of atrial fibrillation early
after cardiac valvular surgery. Am J Cardiol 1998; 82:892.
9. Zaman AG, Archbold RA, Helft G, et al. Atrial fibrillation after coronary artery bypass surgery: a model for
preoperative risk stratification. Circulation 2000; 101:1403.
10. Pires LA, Wagshal AB, Lancey R, Huang SK. Arrhythmias and conduction disturbances after coronary
artery bypass graft surgery: epidemiology, management, and prognosis. Am Heart J 1995; 129:799.
11. Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery. Current
trends and impact on hospital resources. Circulation 1996; 94:390.
12. Mendes LA, Connelly GP, McKenney PA, et al. Right coronary artery stenosis: an independent predictor of
atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 1995; 25:198.
13. Deliargyris EN, Raymond RJ, Guzzo JA, et al. Preoperative factors predisposing to early postoperative
atrial fibrillation after isolated coronary artery bypass grafting. Am J Cardiol 2000; 85:763.
14. Rubin DA, Nieminski KE, Reed GE, Herman MV. Predictors, prevention, and long-term prognosis of atrial
fibrillation after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1987; 94:331.
15. Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative
atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004; 110:124.
16. Buxton AE, Josephson ME. The role of P wave duration as a predictor of postoperative atrial arrhythmias.
Chest 1981; 80:68.
17. Zacharias A, Schwann TA, Riordan CJ, et al. Obesity and risk of new-onset atrial fibrillation after cardiac
surgery. Circulation 2005; 112:3247.
18. Kinoshita T, Asai T, Suzuki T, et al. Preoperative hemoglobin A1c predicts atrial fibrillation after off-pump
coronary bypass surgery. Eur J Cardiothorac Surg 2012; 41:102.
19. Giaccardi M, Macchi C, Colella A, et al. Postacute rehabilitation after coronary surgery: the effect of
preoperative physical activity on the incidence of paroxysmal atrial fibrillation. Am J Phys Med Rehabil
2011; 90:308.
https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 14/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

20. Rader F, Van Wagoner DR, Ellinor PT, et al. Influence of race on atrial fibrillation after cardiac surgery. Circ
Arrhythm Electrophysiol 2011; 4:644.
21. Bramer S, van Straten AH, Soliman Hamad MA, et al. Body mass index predicts new-onset atrial
fibrillation after cardiac surgery. Eur J Cardiothorac Surg 2011; 40:1185.
22. Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of new-onset
atrial fibrillation after cardiac surgery. Crit Care Med 2005; 33:1327.
23. Steinberg JS, Zelenkofske S, Wong SC, et al. Value of the P-wave signal-averaged ECG for predicting
atrial fibrillation after cardiac surgery. Circulation 1993; 88:2618.
24. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the
pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007; 115:135.
25. Bramer S, van Straten AH, Soliman Hamad MA, et al. The impact of new-onset postoperative atrial
fibrillation on mortality after coronary artery bypass grafting. Ann Thorac Surg 2010; 90:443.
26. Wahr JA, Parks R, Boisvert D, et al. Preoperative serum potassium levels and perioperative outcomes in
cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. JAMA 1999;
281:2203.
27. Zaman AG, Alamgir F, Richens T, et al. The role of signal averaged P wave duration and serum
magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery.
Heart 1997; 77:527.
28. Aglio LS, Stanford GG, Maddi R, et al. Hypomagnesemia is common following cardiac surgery. J
Cardiothorac Vasc Anesth 1991; 5:201.
29. Reinhart RA, Marx JJ Jr, Broste SK, Haas RG. Myocardial magnesium: relation to laboratory and clinical
variables in patients undergoing cardiac surgery. J Am Coll Cardiol 1991; 17:651.
30. Kim YM, Kattach H, Ratnatunga C, et al. Association of atrial nicotinamide adenine dinucleotide
phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll
Cardiol 2008; 51:68.
31. Verma A, Marrouche NF, Seshadri N, et al. Importance of ablating all potential right atrial flutter circuits in
postcardiac surgery patients. J Am Coll Cardiol 2004; 44:409.
32. Akar JG, Kok LC, Haines DE, et al. Coexistence of type I atrial flutter and intra-atrial re-entrant
tachycardia in patients with surgically corrected congenital heart disease. J Am Coll Cardiol 2001; 38:377.
33. Seiler J, Schmid DK, Irtel TA, et al. Dual-loop circuits in postoperative atrial macro re-entrant tachycardias.
Heart 2007; 93:325.
34. Wijeysundera DN, Beattie WS, Djaiani G, et al. Off-pump coronary artery surgery for reducing mortality
and morbidity: meta-analysis of randomized and observational studies. J Am Coll Cardiol 2005; 46:872.
35. Athanasiou T, Aziz O, Mangoush O, et al. Do off-pump techniques reduce the incidence of postoperative
atrial fibrillation in elderly patients undergoing coronary artery bypass grafting? Ann Thorac Surg 2004;
77:1567.
36. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump
surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two
randomised controlled trials. Lancet 2002; 359:1194.
37. Almassi GH, Pecsi SA, Collins JF, et al. Predictors and impact of postoperative atrial fibrillation on
patients' outcomes: a report from the Randomized On Versus Off Bypass trial. J Thorac Cardiovasc Surg
2012; 143:93.

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 15/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

38. Cummings JE, Gill I, Akhrass R, et al. Preservation of the anterior fat pad paradoxically decreases the
incidence of postoperative atrial fibrillation in humans. J Am Coll Cardiol 2004; 43:994.
39. White CM, Sander S, Coleman CI, et al. Impact of epicardial anterior fat pad retention on
postcardiothoracic surgery atrial fibrillation incidence: the AFIST-III Study. J Am Coll Cardiol 2007; 49:298.
40. Amar D, Shi W, Hogue CW Jr, et al. Clinical prediction rule for atrial fibrillation after coronary artery
bypass grafting. J Am Coll Cardiol 2004; 44:1248.
41. Villareal RP, Hariharan R, Liu BC, et al. Postoperative atrial fibrillation and mortality after coronary artery
bypass surgery. J Am Coll Cardiol 2004; 43:742.
42. Mariscalco G, Klersy C, Zanobini M, et al. Atrial fibrillation after isolated coronary surgery affects late
survival. Circulation 2008; 118:1612.
43. Soucier RJ, Mirza S, Abordo MG, et al. Predictors of conversion of atrial fibrillation after cardiac operation
in the absence of class I or III antiarrhythmic medications. Ann Thorac Surg 2001; 72:694.
44. Lee JK, Klein GJ, Krahn AD, et al. Rate-control versus conversion strategy in postoperative atrial
fibrillation: a prospective, randomized pilot study. Am Heart J 2000; 140:871.
45. Kowey PR, Stebbins D, Igidbashian L, et al. Clinical outcome of patients who develop PAF after CABG
surgery. Pacing Clin Electrophysiol 2001; 24:191.
46. Landymore RW, Howell F. Recurrent atrial arrhythmias following treatment for postoperative atrial
fibrillation after coronary bypass operations. Eur J Cardiothorac Surg 1991; 5:436.
47. Ambrosetti M, Tramarin R, Griffo R, et al. Late postoperative atrial fibrillation after cardiac surgery: a
national survey within the cardiac rehabilitation setting. J Cardiovasc Med (Hagerstown) 2011; 12:390.
48. Stamou SC, Dangas G, Hill PC, et al. Atrial fibrillation after beating heart surgery. Am J Cardiol 2000;
86:64.
49. Almassi GH, Schowalter T, Nicolosi AC, et al. Atrial fibrillation after cardiac surgery: a major morbid event?
Ann Surg 1997; 226:501.
50. Reed GL 3rd, Singer DE, Picard EH, DeSanctis RW. Stroke following coronary-artery bypass surgery. A
case-control estimate of the risk from carotid bruits. N Engl J Med 1988; 319:1246.
51. Taylor GJ, Malik SA, Colliver JA, et al. Usefulness of atrial fibrillation as a predictor of stroke after isolated
coronary artery bypass grafting. Am J Cardiol 1987; 60:905.
52. Lahtinen J, Biancari F, Salmela E, et al. Postoperative atrial fibrillation is a major cause of stroke after on-
pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77:1241.
53. Hogue CW Jr, Murphy SF, Schechtman KB, Dávila-Román VG. Risk factors for early or delayed stroke
after cardiac surgery. Circulation 1999; 100:642.
54. Lotfi A, Wartak S, Sethi P, et al. Postoperative atrial fibrillation is not associated with an increase risk of
stroke or the type and number of grafts: a single-center retrospective analysis. Clin Cardiol 2011; 34:787.
55. Newman MF, Wolman R, Kanchuger M, et al. Multicenter preoperative stroke risk index for patients
undergoing coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI)
Research Group. Circulation 1996; 94:II74.
56. Mickleborough LL, Walker PM, Takagi Y, et al. Risk factors for stroke in patients undergoing coronary
artery bypass grafting. J Thorac Cardiovasc Surg 1996; 112:1250.
57. Kalavrouziotis D, Buth KJ, Ali IS. The impact of new-onset atrial fibrillation on in-hospital mortality
following cardiac surgery. Chest 2007; 131:833.

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 16/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

58. Saxena A, Dinh DT, Smith JA, et al. Usefulness of postoperative atrial fibrillation as an independent
predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter
Australian study of 19,497 patients). Am J Cardiol 2012; 109:219.
59. Crystal E, Garfinkle MS, Connolly SS, et al. Interventions for preventing post-operative atrial fibrillation in
patients undergoing heart surgery. Cochrane Database Syst Rev 2004; :CD003611.
60. Kim MH, Deeb GM, Morady F, et al. Effect of postoperative atrial fibrillation on length of stay after cardiac
surgery (The Postoperative Atrial Fibrillation in Cardiac Surgery study [PACS(2)]. Am J Cardiol 2001;
87:881.
61. Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in
patients undergoing heart surgery. Cochrane Database Syst Rev 2013; :CD003611.
62. Stephenson LW, MacVaugh H 3rd, Tomasello DN, Josephson ME. Propranolol for prevention of
postoperative cardiac arrhythmias: a randomized study. Ann Thorac Surg 1980; 29:113.
63. Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after
coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 1991; 84:III236.
64. Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug
therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol
1992; 69:963.
65. Khuri SF, Okike ON, Josa M, et al. Efficacy of nadolol in preventing supraventricular tachycardia after
coronary artery bypass grafting. Am J Cardiol 1987; 60:51D.
66. Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in
patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106:75.
67. Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post-operative atrial fibrillation and its
complications after cardiac surgery: a meta-analysis. Eur Heart J 2006; 27:2846.
68. DiNicolantonio JJ, Beavers CJ, Menezes AR, et al. Meta-analysis comparing carvedilol versus metoprolol
for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting. Am J Cardiol
2014; 113:565.
69. Kerin NZ, Jacob S. The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis.
Am J Med 2011; 124:875.e1.
70. Gomes JA, Ip J, Santoni-Rugiu F, et al. Oral d,l sotalol reduces the incidence of postoperative atrial
fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled
study. J Am Coll Cardiol 1999; 34:334.
71. Suttorp MJ, Kingma JH, Peels HO, et al. Effectiveness of sotalol in preventing supraventricular
tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol 1991; 68:1163.
72. Aasbo JD, Lawrence AT, Krishnan K, et al. Amiodarone prophylaxis reduces major cardiovascular
morbidity and length of stay after cardiac surgery: a meta-analysis. Ann Intern Med 2005; 143:327.
73. Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone as prophylaxis against atrial
fibrillation after heart surgery. N Engl J Med 1997; 337:1785.
74. Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart
surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet
2001; 357:830.
75. Guarnieri T, Nolan S, Gottlieb SO, et al. Intravenous amiodarone for the prevention of atrial fibrillation after
open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. J Am Coll Cardiol 1999;
34:343.

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 17/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

76. White CM, Caron MF, Kalus JS, et al. Intravenous plus oral amiodarone, atrial septal pacing, or both
strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II
(AFIST II). Circulation 2003; 108 Suppl 1:II200.
77. Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias
that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized
controlled trial. JAMA 2005; 294:3093.
78. Halonen J, Loponen P, Järvinen O, et al. Metoprolol versus amiodarone in the prevention of atrial
fibrillation after cardiac surgery: a randomized trial. Ann Intern Med 2010; 153:703.
79. Kerstein J, Soodan A, Qamar M, et al. Giving IV and oral amiodarone perioperatively for the prevention of
postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study.
Chest 2004; 126:716.
80. Solomon AJ, Greenberg MD, Kilborn MJ, Katz NM. Amiodarone versus a beta-blocker to prevent atrial
fibrillation after cardiovascular surgery. Am Heart J 2001; 142:811.
81. Harling L, Rasoli S, Vecht JA, et al. Do antioxidant vitamins have an anti-arrhythmic effect following
cardiac surgery? A meta-analysis of randomised controlled trials. Heart 2011; 97:1636.
82. Rodrigo R, Korantzopoulos P, Cereceda M, et al. A randomized controlled trial to prevent post-operative
atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 2013; 62:1457.
83. Blommaert D, Gonzalez M, Mucumbitsi J, et al. Effective prevention of atrial fibrillation by continuous atrial
overdrive pacing after coronary artery bypass surgery. J Am Coll Cardiol 2000; 35:1411.
84. Greenberg MD, Katz NM, Iuliano S, et al. Atrial pacing for the prevention of atrial fibrillation after
cardiovascular surgery. J Am Coll Cardiol 2000; 35:1416.
85. Fan K, Lee KL, Chiu CS, et al. Effects of biatrial pacing in prevention of postoperative atrial fibrillation after
coronary artery bypass surgery. Circulation 2000; 102:755.
86. Daoud EG, Dabir R, Archambeau M, et al. Randomized, double-blind trial of simultaneous right and left
atrial epicardial pacing for prevention of post-open heart surgery atrial fibrillation. Circulation 2000;
102:761.
87. Levy T, Fotopoulos G, Walker S, et al. Randomized controlled study investigating the effect of biatrial
pacing in prevention of atrial fibrillation after coronary artery bypass grafting. Circulation 2000; 102:1382.
88. Gerstenfeld EP, Hill MR, French SN, et al. Evaluation of right atrial and biatrial temporary pacing for the
prevention of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 1999; 33:1981.
89. Chung MK, Augostini RS, Asher CR, et al. Ineffectiveness and potential proarrhythmia of atrial pacing for
atrial fibrillation prevention after coronary artery bypass grafting. Ann Thorac Surg 2000; 69:1057.
90. Weiner B, Rheinlander HF, Decker EL, Cleveland RJ. Digoxin prophylaxis following coronary artery
bypass surgery. Clin Pharm 1986; 5:55.
91. Gold MR, O'Gara PT, Buckley MJ, DeSanctis RW. Efficacy and safety of procainamide in preventing
arrhythmias after coronary artery bypass surgery. Am J Cardiol 1996; 78:975.
92. Laub GW, Janeira L, Muralidharan S, et al. Prophylactic procainamide for prevention of atrial fibrillation
after coronary artery bypass grafting: a prospective, double-blind, randomized, placebo-controlled pilot
study. Crit Care Med 1993; 21:1474.
93. Davison R, Hartz R, Kaplan K, et al. Prophylaxis of supraventricular tachyarrhythmia after coronary
bypass surgery with oral verapamil: a randomized, double-blind trial. Ann Thorac Surg 1985; 39:336.
94. Smith EE, Shore DF, Monro JL, Ross JK. Oral verapamil fails to prevent supraventricular tachycardia
following coronary artery surgery. Int J Cardiol 1985; 9:37.
https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 18/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

95. Malhotra R, Mishra M, Kler TS, et al. Cardioprotective effects of diltiazem infusion in the perioperative
period. Eur J Cardiothorac Surg 1997; 12:420.
96. Seitelberger R, Hannes W, Gleichauf M, et al. Effects of diltiazem on perioperative ischemia, arrhythmias,
and myocardial function in patients undergoing elective coronary bypass grafting. J Thorac Cardiovasc
Surg 1994; 107:811.
97. Shiga T, Wajima Z, Inoue T, Ogawa R. Magnesium prophylaxis for arrhythmias after cardiac surgery: a
meta-analysis of randomized controlled trials. Am J Med 2004; 117:325.
98. England MR, Gordon G, Salem M, Chernow B. Magnesium administration and dysrhythmias after cardiac
surgery. A placebo-controlled, double-blind, randomized trial. JAMA 1992; 268:2395.
99. Kaplan M, Kut MS, Icer UA, Demirtas MM. Intravenous magnesium sulfate prophylaxis for atrial fibrillation
after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125:344.
100. Toraman F, Karabulut EH, Alhan HC, et al. Magnesium infusion dramatically decreases the incidence of
atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2001; 72:1256.
101. Hazelrigg SR, Boley TM, Cetindag IB, et al. The efficacy of supplemental magnesium in reducing atrial
fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2004; 77:824.
102. Cook RC, Humphries KH, Gin K, et al. Prophylactic intravenous magnesium sulphate in addition to oral
{beta}-blockade does not prevent atrial arrhythmias after coronary artery or valvular heart surgery: a
randomized, controlled trial. Circulation 2009; 120:S163.
103. Gu WJ, Wu ZJ, Wang PF, et al. Intravenous magnesium prevents atrial fibrillation after coronary artery
bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials. Trials
2012; 13:41.
104. Pretorius M, Murray KT, Yu C, et al. Angiotensin-converting enzyme inhibition or mineralocorticoid
receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit
Care Med 2012; 40:2805.
105. Shariff N, Zelenkofske S, Eid S, et al. Demographic determinants and effect of pre-operative angiotensin
converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after
CABG surgery. BMC Cardiovasc Disord 2010; 10:7.
106. Coleman CI, Makanji S, Kluger J, White CM. Effect of angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation. Ann
Pharmacother 2007; 41:433.
107. White CM, Kluger J, Lertsburapa K, et al. Effect of preoperative angiotensin converting enzyme inhibitor or
angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study
from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg 2007; 31:817.
108. Bandeali SJ, Kayani WT, Lee VV, et al. Outcomes of preoperative angiotensin-converting enzyme inhibitor
therapy in patients undergoing isolated coronary artery bypass grafting. Am J Cardiol 2012; 110:919.
109. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial
fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of
MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114:1455.
110. Zheng Z, Jayaram R, Jiang L, et al. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016;
374:1744.
111. Liakopoulos OJ, Kuhn EW, Slottosch I, et al. Preoperative statin therapy for patients undergoing cardiac
surgery. Cochrane Database Syst Rev 2012; :CD008493.

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 19/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

112. Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy for patients undergoing
cardiac surgery. Cochrane Database Syst Rev 2015; :CD008493.
113. Ozaydin M, Peker O, Erdogan D, et al. N-acetylcysteine for the prevention of postoperative atrial
fibrillation: a prospective, randomized, placebo-controlled pilot study. Eur Heart J 2008; 29:625.
114. Ozaydin M, Icli A, Yucel H, et al. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-
operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. Eur Heart J 2013;
34:597.
115. Imazio M, Brucato A, Ferrazzi P, et al. Colchicine reduces postoperative atrial fibrillation: results of the
Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy.
Circulation 2011; 124:2290.
116. Imazio M, Brucato A, Ferrazzi P, et al. Colchicine for prevention of postpericardiotomy syndrome and
postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA 2014; 312:1016.
117. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients
with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task
Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.
118. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients
with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart
Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071.
119. Horbach SJ, Lopes RD, da C Guaragna JC, et al. Naproxen as prophylaxis against atrial fibrillation after
cardiac surgery: the NAFARM randomized trial. Am J Med 2011; 124:1036.
120. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response
meta-analysis. Circulation 2009; 119:1853.
121. Dieleman JM, van Paassen J, van Dijk D, et al. Prophylactic corticosteroids for cardiopulmonary bypass in
adults. Cochrane Database Syst Rev 2011; :CD005566.
122. Whitlock RP, Devereaux PJ, Teoh KH, et al. Methylprednisolone in patients undergoing cardiopulmonary
bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386:1243.
123. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients
With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines
(Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).
J Am Coll Cardiol. 2006; 48:e149.
124. Solomon AJ, Kouretas PC, Hopkins RA, et al. Early discharge of patients with new-onset atrial fibrillation
after cardiovascular surgery. Am Heart J 1998; 135:557.
125. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al.
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation
of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.
126. Geelen P, O'Hara GE, Roy N, et al. Comparison of propafenone versus procainamide for the acute
treatment of atrial fibrillation after cardiac surgery. Am J Cardiol 1999; 84:345.
127. McAlister HF, Luke RA, Whitlock RM, Smith WM. Intravenous amiodarone bolus versus oral quinidine for
atrial flutter and fibrillation after cardiac operations. J Thorac Cardiovasc Surg 1990; 99:911.
128. Gavaghan TP, Koegh AM, Kelly RP, et al. Flecainide compared with a combination of digoxin and
disopyramide for acute atrial arrhythmias after cardiopulmonary bypass. Br Heart J 1988; 60:497.

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 20/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

129. Di Biasi P, Scrofani R, Paje A, et al. Intravenous amiodarone vs propafenone for atrial fibrillation and
flutter after cardiac operation. Eur J Cardiothorac Surg 1995; 9:587.
130. Campbell TJ, Gavaghan TP, Morgan JJ. Intravenous sotalol for the treatment of atrial fibrillation and flutter
after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. Br Heart
J 1985; 54:86.
131. VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of
atrial arrhythmias after cardiac surgery. Circulation 1999; 100:369.
132. Yilmaz AT, Demírkiliç U, Arslan M, et al. Long-term prevention of atrial fibrillation after coronary artery
bypass surgery: comparison of quinidine, verapamil, and amiodarone in maintaining sinus rhythm. J Card
Surg 1996; 11:61.
133. Connolly SJ, Mulji AS, Hoffert DL, et al. Randomized placebo-controlled trial of propafenone for treatment
of atrial tachyarrhythmias after cardiac surgery. J Am Coll Cardiol 1987; 10:1145.
134. Hjelms E. Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with
digoxin treatment. Scand J Thorac Cardiovasc Surg 1992; 26:193.
135. Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate Control versus Rhythm Control for Atrial Fibrillation after
Cardiac Surgery. N Engl J Med 2016; 374:1911.
136. Kollar A, Lick SD, Vasquez KN, Conti VR. Relationship of atrial fibrillation and stroke after coronary artery
bypass graft surgery: when is anticoagulation indicated? Ann Thorac Surg 2006; 82:515.
137. Gohlke H, Gohlke-Bärwolf C, Stürzenhofecker P, et al. Improved graft patency with anticoagulant therapy
after aortocoronary bypass surgery: a prospective, randomized study. Circulation 1981; 64:II22.
138. Weber MA, Hasford J, Taillens C, et al. Low-dose aspirin versus anticoagulants for prevention of coronary
graft occlusion. Am J Cardiol 1990; 66:1464.
139. Malouf JF, Alam S, Gharzeddine W, Stefadouros MA. The role of anticoagulation in the development of
pericardial effusion and late tamponade after cardiac surgery. Eur Heart J 1993; 14:1451.
140. Anderson E, Johnke K, Leedahl D, et al. Novel oral anticoagulants vs warfarin for the management of
postoperative atrial fibrillation: clinical outcomes and cost analysis. Am J Surg 2015; 210:1095.
141. Dunning J, Nagendran M, Alfieri OR, et al. Guideline for the surgical treatment of atrial fibrillation. Eur J
Cardiothorac Surg 2013; 44:777.
142. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft
Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic
Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll
Cardiol 2011; 58:e123.
143. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients
with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines
(Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation):
developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
Circulation 2006; 114:e257.
144. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation
developed in collaboration with EACTS. Eur Heart J 2016; 37:2893.

Topic 1011 Version 39.0

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 21/22
7/11/2017 Atrial fibrillation and flutter after cardiac surgery - UpToDate

https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery?source=search_result&search=fibrilaci%C3%B3n%20auricular… 22/22

Vous aimerez peut-être aussi